Fig. 1From: Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBOA Therapy survival of patients treated with Benepali® (n=83) and B therapy survival of Benepali® in comparison to Enbrel® in patients matched by the number of bDMARD treatment courses in the past, JIA category, sex, ANA positivity, and disease duration at treatment start (± 3 years)Back to article page